Helius Medical Technologies - Home


Call us: +1 877-564-0008


Stock Quote - HSDT

*Delayed quote courtesy of Google.

NEWTOWN, PA – Helius Medical Technologies, Inc. (CSE: HSM) (“HMT”, or the “Company”) is pleased to announce today that U.S. Patent No. 8,849,407, “Non-Invasive Neuromodulation (NINM) for Rehabilitation of Brain Function,” has been granted by the US Patent Office (USPTO). Helius has an exclusive license to this patent, which is core to protecting the Portable NeuroModulation Stimulator (PoNS™) device and the associated therapeutic modality. The PoNS™, an investigational medical device that induces neuromodulation by stimulating the cranial nerves found in the tongue, is initially being studied for the treatment of balance disorder symptoms caused by Traumatic Brain Injury (“TBI”) and Multiple Sclerosis.

Helius’ patent strategy, which is being executed by Joe Capraro and his team at Proskauer Rose LLP, is to pursue patent protection for the core platform technology as well to patent protect evolving device design concepts. Helius has numerous other patent applications either in process or pending adjudication from the USPTO.

“Protecting the broad applicability of the Helius technology is core to the creation of shareholder value. This, combined with clinical programs designed to prove applicability for the PoNS device in the treatment of a wide range of neurological symptoms, regardless of the underlying disease state, is anticipated to align the interest of the shareholders, the medical community and most importantly, the patients,” said Philippe Deschamps, Chief Executive Officer of Helius.

About Helius Medical Technologies (HMT)

Helius Medical Technologies is a medical technology holding company focused on neurological wellness. HMT seeks to use unique and non-invasive platform technologies that create portals to the brain to amplify its ability to heal itself. HMT intends to file for U.S. Food and Drug Administration clearance for the PoNS™ device. For more information, please visit www.heliusmedical.com.

The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

Safe Harbor Statement

All statements in this news release, other than statements of historical facts, are forward-looking statements. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include risks detailed from time to time in the filings made by the Company with securities regulators.

The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company assumes no obligation to update the forward-looking statements except as required by applicable law.